NVCR

Latest SEC Filings & News for NVCR

2 most recent filings and news items mentioning NVCR. Updated every 60 seconds.

Get this data via API — free tier: 10,000 calls/day

curl "https://api.brieftape.com/v1/tickers/NVCR/news?limit=20"

Pull NVCR filings straight into your trading bot, model, or app.

Get an API key — free tier: 10,000 calls/day

RegulatoryJun 30, 2026Positive

Novocure Optune Pax Receives CE Mark for Pancreatic Cancer

Novocure's Optune Pax device received a CE Mark for locally advanced pancreatic cancer supported by significant overall survival improvements in the PANOVA-3 trial. This regulatory milestone expands the device's market reach and addresses the critical need for effective therapies

View filing at SEC.gov →

RegulatoryJun 18, 2026Negative

NovoCure's Phase 3 TRIDENT trial misses primary endpoint for earlier TTFields therapy

NovoCure announced topline results from its Phase 3 TRIDENT trial evaluating earlier initiation of Tumor Treating Fields therapy in newly diagnosed glioblastoma, which failed to meet its primary endpoint of demonstrating statistically significant overall survival improvement. The

View filing at SEC.gov →

AI-summarized public filings for informational purposes only. Not investment advice. Always verify against the original filing at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.